^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Cancer

    Related cancers:
    1d
    RAMP201J: A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Verastem, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    1d
    Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel
    1d
    HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=468, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • mocertatug rezetecan (GSK5733584)
    1d
    A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer (clinicaltrials.gov)
    P1, N=27, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel
    2d
    Feasibility of CALM in Patients With Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    2d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline
    New P3 trial • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    2d
    Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, University Health Network, Toronto
    New P3 trial
    2d
    Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma. (PubMed, Bull Cancer)
    MEK inhibitors, especially trametinib and avutometinib in combination with defactinib, have recently demonstrated improved outcomes in recurrent disease, while new combination strategies are under active evaluation to overcome resistance mechanisms. Immunotherapy remains of limited efficacy, though biomarker-driven combinations are explored. Ongoing biomarker-guided trials are expected to refine treatment paradigms.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    Mekinist (trametinib) • Avmapki (avutometinib) • Fakzynja (defactinib)
    2d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    2d
    Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment (clinicaltrials.gov)
    P2, N=20, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    carboplatin
    2d
    QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    3d
    GLI1-rearranged mesenchymal tumor of the ovary with a novel ACTG1::GLI1 fusion. (PubMed, Virchows Arch)
    Histopathological examination confirmed a GLI1-altered mesenchymal tumor, and RNA sequencing identified a novel ACTG1::GLI1 fusion, representing the first documented case of ACTG1 as a fusion partner for GLI1. By reviewing the literature, we further characterize the morphologic, immunophenotypic, and molecular genetic spectrum of this rare ovarian neoplasm, expanding the known diversity of GLI1-associated fusions in mesenchymal tumors.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • ACTG1 (Actin Gamma 1)